Exo-S-mecamylamine formulation and use in treatment
A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.
1. A method of treating a medical condition selected from the group consisting of substance addiction, Tourette's Syndrome, a neuropsychiatric disorder, depression, and anxiety, in a human in need thereof, comprising orally administering a therapeutically effective amount of a pharmaceutical composition to the human, wherein the pharmaceutical composition comprises:
exo-S-mecamylamine or pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine or a pharmaceutically acceptable salt thereof,
one or more pharmaceutically acceptable carriers; and
a pharmaceutical adjuvant, wherein the pharmaceutical composition has a higher overall therapeutic index than the same amount of exo-R-mecamylamine substantially free of exo-S-mecamylamine.
2. The method of claim 1 , wherein the pharmaceutical composition is a unit dosage form.
3. The method of claim 2 , wherein the unit dosage form is selected from the group consisting of a tablet, capsule, soft gelatin capsule, hard gelatin capsule, powder, lozenge, gum, emulsion, suspension, syrup, and solution.
4. The method of claim 1 , wherein the pharmaceutical composition is formulated to provide rapid, sustained, or delayed release of the exo-S-mecamylamine or a pharmaceutically acceptable salt thereof.
5. The method of claim 1 , wherein the effective amount of exo-S-mecamylamine or pharmaceutically acceptable salt thereof is from about 0.001 mg/kg to about 6 mg/kg per day.
6. The method of claim 1 , wherein the effective amount of exo-S-mecamylamine or pharmaceutically acceptable salt thereof is from about 0.01 mg/kg to about 1.5 mg/kg per day.
7. The method of claim 1 , wherein the medical condition is substance addiction.
8. The method of claim 1 , wherein the medical condition is Tourette's Syndrome.
9. The method of claim 1 , wherein the medical condition is a neuropsychiatric disorder.
10. The method of claim 1 , wherein the medical condition is depression.
11. The method of claim 1 , wherein the medical condition is anxiety.